Pamela Stephenson
Corporate Officer/Principal bei DISC MEDICINE, INC.
Vermögen: 972 382 $ am 30.04.2024
Profil
Pamela Stephenson is currently the Chief Commercial Officer at Disc Medicine, Inc. Her former positions include being an Independent Director at Zynerba Pharmaceuticals, Inc. from 2019 to 2023, and Vice President-Global Market Access & Value at Vertex Pharmaceuticals, Inc. from 2008 to 2019.
She also served as the Chief Commercial Officer at Albireo Pharma, Inc. Ms. Stephenson received her undergraduate degree from Brown University and her graduate degree from Boston University School of Public Health.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DISC MEDICINE, INC.
0,15% | 26.02.2024 | 36 666 ( 0,15% ) | 972 382 $ | 30.04.2024 |
Aktive Positionen von Pamela Stephenson
| Unternehmen | Position | Beginn |
|---|---|---|
| DISC MEDICINE, INC. | Corporate Officer/Principal | 26.02.2024 |
Ehemalige bekannte Positionen von Pamela Stephenson
| Unternehmen | Position | Ende |
|---|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 10.10.2023 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01.03.2019 |
| ALBIREO PHARMA, INC. | Corporate Officer/Principal | - |
Ausbildung von Pamela Stephenson
| Brown University | Undergraduate Degree |
| Boston University School of Public Health | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| DISC MEDICINE, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
